2022 closed with a 2% drop in turnover, but a 70% drop in net income, but 2021 was "inflated" by the sale of Roche shares
Novartis closed 2022 with turnover down 2% compared to a year earlier. Net profit, on the other hand, has plummeted to almost 7 billion dollars, with a 70% minus compared to 2021 (24 billion), but this is a collapse due to very specific reasons. Indeed, a reason: in 2021, 15 billion dollars of profits from the sale of Roche shares were recorded which inflated the net benefit.
As for turnover, it stood at just over 50 billion francs, one billion less than in 2021.
There were two major strategic decisions made by the Basel multinational in 2022. The first was to focus on innovative medicines in a so-called "pure.play" context, i.e. focusing on a few areas of expertise. Today there are five such areas: cancer, cardiovascular disease, neuroscience, hematology and immunology.
The second decision made in August is to separate from a historic name in the pharmaceutical world, namely Sandoz, which is more focused on generic drugs. The company will become independent in the second half of this year. Discussions are currently ongoing with all stakeholders, including workers' representatives.
Related news: A significantly smaller gain for the Novartis CEO in 2022
